MALVERN, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- CubeSmart (NYSE: CUBE) today announced its operating results for the three and six months ended June 30, 2025. “The rental season saw modestly better seasonal performance compared to last year as key operating metrics maintained their positive momentum throughout the second quarter and into July,” commented President and Chief Executive Officer Christopher P. Marr. “Fundamentals have continued to stabilize, supported by a lessening impact of new supply, better ...

Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and developmentRADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug developm ...

Partnership aims to utilize predictive AI to help identify arrhythmias earlier in patient populations with an elevated risk for arrhythmias to enable timely care for millions who remain undiagnosedCommercial offering from this collaboration designed to support scalable population health and value-based care strategies SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a digital health leader focused on creating trusted solutions that detect, predict, and prevent disea ...

FREMONT, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Enovix Corporation (Nasdaq: ENVX, ENVXW) (“Enovix”), a global high-performance battery company, announced that it posted on its website here a letter to shareholders from President and CEO, Dr. Raj Talluri, and CFO, Ryan Benton, discussing the company’s second quarter 2025 results. The company will host a live webcast at 5:00 PM ET / 2:00 PM PT to discuss the results and provide business updates. To register for the webcast, please visit: https://enovix-q2- ...

GUANGZHOU, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- YSX TECH. CO., LTD (the “Company,” “our,” “us” or “YSXT”), a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China, today announced its financial results for the fiscal year ended March 31, 2025. Key Financial Metrics for Fiscal Year 2025 Total revenue grew by approximately 22.0% to approximately $71.5 million in the fiscal year ...

Second Quarter Results Total revenues of $36.5 million, a 23% year-over-year improvementNet income of $0.9 million and diluted earnings per share of $0.34, which includes a positive impact of $1.4 million related to the release of our deferred tax valuation allowance in CanadaAdjusted EBITDA of $2.2 million, a $1.3 million year-over-year improvement $25.4 million in cash and $7.7 million of total debt as of June 30, 2025 HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- NCS Multistage Holdings, Inc. (Nasdaq: NCSM) ...

WOBURN, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it entered into a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. T ...

文章核心观点 公司2025年第二季度运营成果出色，各业务板块销售和盈利均有增长，基于良好表现上调全年业绩指引 [1][5] 各部分总结 第二季度业绩 - 综合净销售额达60亿美元，增长11.1%，按固定汇率计算增长10.3%，有机净销售额增长10.2% [2] - 医疗外科和神经科技业务净销售额38亿美元，增长17.3%，按固定汇率计算增长16.7%，有机净销售额增长11.0% [2] - 骨科业务净销售额22亿美元，增长2.0%，按固定汇率计算增长1.1%，排除脊柱植入业务剥离影响，增长10.7%和9.7%，有机净销售额增长9.0% [3] - 报告净收益8.84亿美元，增长7.2%，摊薄后每股净收益2.29美元，增长7.0% [4] - 报告毛利率63.8%，营业利润率18.5%，调整后毛利率65.4%，营业利润率25.7%，调整后净收益12亿美元，增长11.6%，摊薄后每股净收益3.13美元，增长11.4% [4] 2025年展望 - 上调全年指引，预计有机净销售额增长9.5% - 10.0%，调整后摊薄每股净收益13.40 - 13.60美元 [5] - 销售指引含适度有利定价影响，外汇若维持当前水平，对销售和调整后每股净收益有轻微积极影响 [6] - 预计2025年关税净影响约1.75亿美元 [7] 非GAAP财务指标 - 公司补充非GAAP财务指标，包括固定汇率销售增长百分比、有机销售增长百分比等，认为这些指标有助于投资者理解财务结果和评估未来业绩 [29] - 计算固定汇率销售增长百分比需消除外汇汇率变化影响，计算有机销售增长百分比需消除外汇汇率、收购和剥离影响，计算收益表现需排除影响运营结果可比性和收益趋势的特定项目 [30] 销售增长分析 - 按地域，美国销售额45.54亿美元，增长12.5%，国际销售额14.68亿美元，增长6.8% [25] - 按业务板块，医疗外科和神经科技业务销售额37.71亿美元，增长17.3%，骨科业务销售额22.51亿美元，增长2.0% [25] 补充销售增长分析 - 医疗外科和神经科技业务各细分领域有不同程度增长，如血管业务增长52.3% [27] - 骨科业务各细分领域也有增长，如创伤和四肢业务增长15.0% [27] 非GAAP与GAAP财务指标调节 - 详细列出了各项调整项目对GAAP财务指标的影响，如收购和整合相关成本、无形资产摊销等 [33][34][35]

SAN JOSE, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Zoom Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the second quarter of fiscal year 2026 on Thursday, August 21, 2025, after the market closes. A live Zoom Webinar of the event can be accessed at 2:00 pm PT / 5:00 pm ET through Zoom’s investor relations website at https://investors.zoom.com. A replay will be available approximately two hours after the conclusion of the live event. About ZoomZoom’s mission is t ...

WESTBROOK, Maine, July 31, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a fast-growing consumer health and wellness company, announced today that it plans to release financial results for the second quarter ended June 30, 2025, on Thursday, August 14, 2025, before the open of market trading. In conjunction with reporting second quarter 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company’s Chief Executive Officer, Jack R ...